Relationship between serum osteoprotegerin, glycemic control, renal function and markers of atherosclerosis in type 2 diabetes

References

• Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002;22:549–53.
   PubMed Web of Science ®Google Scholar
• Aubin JE, Bonnelye E. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos Int 2000;11:905–13.
   PubMed Web of Science ®Google Scholar
• Van Campenhout A, Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 2009;204: 321–29.
   PubMed Web of Science ®Google Scholar
• Bennett BJ, Scatena M, Kirk EA, Rattazzi M, Varon RM, Averill M, Schwartz SM, Giachelli CM, Rosenfeld ME. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/-mice. Arterioscler Thromb Vasc Biol 2006;26:2117–24.
   PubMed Web of Science ®Google Scholar
• Nybo M, Rasmussen LM. The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review. Eur J Endocrinol 2008;159:603–8.
   PubMed Web of Science ®Google Scholar
• Nabipour I, Kalantarhormozi M, Larijani B, Assadi M, Sanjdideh Z. Osteoprotegerin in relation to type 2 diabetes mellitus and the metabolic syndrome in postmenopausal women. Metabolism 2010;59:742–7.
   PubMed Web of Science ®Google Scholar
• Xiang GD, Xu L, Zhao LS, Yue L, Hou J. The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetes. Diabetes 2006;55: 2126–31.
   PubMed Web of Science ®Google Scholar
• Avignon A, Sultan A, Piot C, Elaerts S, Cristol JP, Dupuy AM. Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. Diabetes Care 2005;28:2176–80.
   PubMed Web of Science ®Google Scholar
• Anand DV, Lahiri A, Lim E, Hopkins D, Corder R. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 2006;47:1850–7.
   PubMed Web of Science ®Google Scholar
• Jung CH, Lee WY, Kim SY, Jung JH, Rhee EJ, Park CY, Mok JO, Oh KW, Kim CH, Park SW, Kim SW. The relationship between coronary artery calcification score, plasma osteoprotegerin level and arterial stiffness in asymptomatic type 2 DM. Acta Diabetol 2010;47(Suppl. 1):145–52.
   PubMedGoogle Scholar
• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004;27:S5–10.
   PubMedGoogle Scholar
• Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412–9.
   PubMed Web of Science ®Google Scholar
• Terekeci HM, Senol MG, Top C, Sahan B, Celik S, Sayan O, Kucukardali Y, Ipcioglu O, Cagiltay E, Oktenli C, Ozata M. Plasma osteoprotegerin concentrations in type 2 diabetic patients and its association with neuropathy. Exp Clin Endocrinol Diabetes 2009;117:119–23.
   PubMed Web of Science ®Google Scholar
• Xiang GD, Pu JH, Zhao LS, Sun HL, Hou J, Yue L. Association between plasma osteoprotegerin concentrations and urinary albumin excretion in Type 2 diabetes. Diabet Med 2009;26:397–403.
   PubMed Web of Science ®Google Scholar
• Knudsen ST, Foss CH, Poulsen PL, Andersen NH, Mogensen CE, Rasmussen LM. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol 2003;149: 39–42.
   PubMed Web of Science ®Google Scholar
• Gannagé-Yared MH, Fares F, Semaan M, Khalife S, Jambart S. Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population. Clin Endocrinol (Oxf) 2006; 64:652–8.
   PubMed Web of Science ®Google Scholar
• Knudsen ST, Jeppesen P, Poulsen PL, Andersen NH, Bek T, Schmitz O, Mogensen CE, Rasmussen LM. Plasma concentrations of osteoprotegerin during normo- and hyperglycaemic clamping. Scand J Clin Lab Invest 2007;67:135–42.
   PubMed Web of Science ®Google Scholar
• Hofsø D, Ueland T, Hager H, Jenssen T, Bollerslev J, Godang K, Aukrust P, Røislien J, Hjelmesaeth J. Inflammatory mediators in morbidly obese subjects: associations with glucose abnormalities and changes after oral glucose. Eur J Endocrinol 2009;161:451–8.
   PubMed Web of Science ®Google Scholar
• Yaturu S, Rains J, Jain SK. Relationship of elevated osteoprotegerin with insulin resistance, CRP, and TNF-alpha levels in men with type 2 diabetes. Cytokine 2008;44: 168–71.
   PubMed Web of Science ®Google Scholar
• Gannagé-Yared MH, Yaghi C, Habre B, Khalife S, Noun R, Germanos-Haddad M, Trak-Smayra V. Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study. Eur J Endocrinol 2008;158:353–9.
   PubMed Web of Science ®Google Scholar
• Oh ES, Rhee EJ, Oh KW, Lee WY, Baek KH, Yoon KH, Kang MI, Yun EJ, Park CY, Choi MG, Yoo HJ, Park SW. Circulating osteoprotegerin levels are associated with age, waist-to-hip ratio, serum total cholesterol, and low-density lipoprotein cholesterol levels in healthy Korean women. Metabolism 2005;54:49–54.
   PubMed Web of Science ®Google Scholar
• Gonnelli S, Montagnani A, Caffarelli C, Cadirni A, Campagna MS, Franci MB, Lucani B, Gaggiotti E, Nuti R. Osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANK-L) serum levels in patients on chronic hemodialysis. J Endocrinol Invest 2005;28:534–9.
   PubMed Web of Science ®Google Scholar
• Szulc P, Hofbauer LC, Heufelder AE, Roth S, Delmas PD. Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab 2001;86:3162–5.
   PubMed Web of Science ®Google Scholar
• Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA 2003;290:932–40.
   PubMed Web of Science ®Google Scholar
• Vik A, Mathiesen EB, Johnsen SH, Brox J, Wilsgaard T, Njølstad I, Hansen JB. Serum osteoprotegerin, sRANKL and carotid plaque formation and growth in a general population – The Tromsø Study. J Thromb Haemost 2010;8: 898–905.
   PubMed Web of Science ®Google Scholar